Ecuador vs Germany: HIV/AIDS deaths averted by antiretroviral therapy
Ecuador
3,034 deaths
in 2024
Germany
2,906 deaths
in 2024
Ecuador rank
49th
Germany rank
51st
HIV/AIDS deaths averted by antiretroviral therapy over time
- Ecuador
- Germany
How they compare
Ecuador currently reports 3,034 deaths against 2,906 deaths in Germany, a difference of 128 deaths.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Germany ahead.
Ecuador ranks 49th and Germany ranks 51st of 157 countries.
Across the 4 decades both report, Ecuador averaged higher in 1 and Germany in 3.
Head to head by decade
| Decade | Ecuador | Germany | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 26.07 deaths | 1,195 deaths | 1,169 deaths | Germany |
| 2000s | 314.14 deaths | 2,173 deaths | 1,859 deaths | Germany |
| 2010s | 1,733 deaths | 2,484 deaths | 750.65 deaths | Germany |
| 2020s | 2,906 deaths | 2,825 deaths | 81.06 deaths | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Ecuador or Germany?
- Ecuador, at 3,034 deaths against 2,906 deaths in Germany as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Ecuador and Germany?
- 128 deaths, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Germany?
- 35 years are reported by both, from 1990 to 2024.
- How do Ecuador and Germany rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Ecuador ranks 49th and Germany ranks 51st of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.